Last updated on September 2018

A Treatment Study of Mucopolysaccharidosis Type IIIB


Brief description of study

The study's primary objectives are to evaluate the safety and tolerability of BMN 250 administered to subjects with MPS IIIB via an ICV reservoir and catheter and to evaluate the impact of BMN 250 on cognitive function in patients with MPS IIIB as assessed by the Development Quotient.

Clinical Study Identifier: NCT02754076

Contact Investigators or Research Sites near you

Start Over

BioMarin Trial Inquiries

Hospital Clinico Universitario de Santiago
Santiago de Compostela, Spain
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.